Clinical Data submits antidepressant with companion Dx
This article was originally published in Pharmaceutical Approvals Monthly
Clinical Data submits its NDA for vilazodone, a dual-acting selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist, for the treatment of major depressive disorder. In two eight-week Phase III trials, vilazodone was superior to placebo, with statistical significance for the primary and multiple secondary endpoints. Vilazodone would be set apart on the market by the availability of a companion diagnostic to identify patients most likely to benefit from treatment. Clinical Data is co-developing the test along with the drug. It estimates that peak sales could surpass $2 billion with the companion diagnostic (1"The Pink Sheet" DAILY, April 8, 2009)
You may also be interested in...
Company anticipates data from a second Phase III trial evaluating the SSRI/5HT1A partial agonist for depression in the second quarter.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.